Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

Date of occurrence: June 11, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass media: CNA News E-Paper Content reported: During the preparation court hearing on OBI’s insider trading case on June 9, Michael Chang emphasized that OBI’s novel […]

This article is password protected.

To view the content, please enter your password in the field below